Inclusion Criteria:

• All patients must be diagnosed with non-small cell lung cancer (Stage IIIA non surgical, IIIB or IV).
• All patients must be within 12 months of their primary lung cancer diagnosis or metastatic or recurrence disease.
• All patients must be at least 18 years of age.
• All patients must have an ECOG Performance Status rating of level 0, 1 or 2. If patients have brain metastases, they must be stable.
• All patients must be under the care of a clinician who has consented to participate in the study.
• All patients must be able to speak and read English (educational attainment of at least 6th grade).
• All patients will be invited to have a caregiver also participate in the study, however this is not required.

Exclusion Criteria:

• 1. Patients receiving anticoagulation therapy. 2. Patients who have received prior gemcitabine or radiation therapy to the lung bed 3. Patients receiving any other investigational agents. 4. Patients with known brain metastases will be excluded because of their poor prognosis and because they often develop progressive neurological dysfunction that would confound the evaluation of neurological and other adverse effects.
• Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
• Patients who test positive for Hepatitis B virus, Hepatitis C virus or HIV. 7. level 3 hypertension; 8. severe coronary disease; 9. myelosuppression; 10. respiratory disease;
• brain metastasis; 12. chronic infections